| 1 | Portal Vein Recanalization Transjugular Intrahepatic Portosystemic Shunt for Noncirrhotic Chronic Portal Vein Thrombosis Leading to Successful Pregnancy: Case Report | 1.1 | 1 | Citations (PDF) |
| 2 | Yttrium-90 Radiation Segmentectomy for Treatment of Neuroendocrine Liver Metastases | 1.1 | 9 | Citations (PDF) |
| 3 | Yttrium-90 Radioembolization Has Become the Most Utilized Bridging Treatment for Liver Transplant Candidates in the United States | 1.1 | 19 | Citations (PDF) |
| 4 | Erratum for: Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma | 8.7 | 0 | Citations (PDF) |
| 5 | Escalated Segmental and Modified Radiation Lobectomy Dosing for Yttrium-90 Radioembolization of Liver-Dominant Metastatic Colorectal Cancer: 10-year Outcomes | 2.6 | 1 | Citations (PDF) |
| 6 | Advances in radiation therapy for HCC: Integration with liver-directed treatments | 4.5 | 3 | Citations (PDF) |
| 7 | Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group | 5.5 | 6 | Citations (PDF) |
| 8 | Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma | 0.9 | 27 | Citations (PDF) |
| 9 | Letter to the Editor: TIPS for noncirrhotic adults with chronic mesenteric venous thrombosis and EHPVO refractory to standard-of-care therapy—How are they doing in 2025? | 10.1 | 0 | Citations (PDF) |
| 10 | Liver-Directed Therapies in Colorectal Cancer: Old Hats and New Tricks | 4.4 | 2 | Citations (PDF) |
| 11 | Design and optimization of imageable microspheres for locoregional cancer therapy | 3.4 | 2 | Citations (PDF) |
| 12 | Interventional radiology meets immuno-oncology for hepatocellular carcinoma | 4.2 | 17 | Citations (PDF) |
| 13 | Adverse Events of Surgical Drain Placement: An Analysis of the NSQIP Database | 1.1 | 7 | Citations (PDF) |
| 14 | Patient-Reported Outcomes: Updates since the 2017 Society of Interventional Radiology Foundation Research Consensus Panel | 1.1 | 2 | Citations (PDF) |
| 15 | Portal Hypertension after Portal Vein Reconstruction-Transjugular Intrahepatic Portosystemic Shunt Creation Due to Iatrogenic Splenic Arteriovenous Shunt | 1.1 | 0 | Citations (PDF) |
| 16 | Abstract No. 8 Percutaneous Endobiliary Radiofrequency Ablation in the Management of Resistant Benign Biliary Strictures | 1.1 | 0 | Citations (PDF) |
| 17 | Abstract No. 99 Effect of Salvage Prostate Artery Embolization for Recurrent or Refractory Urinary Symptoms After Minimally Invasive Surgical Techniques | 1.1 | 0 | Citations (PDF) |
| 18 | Multicenter Quantification of Radiation Exposure and Associated Risks for Prostatic Artery Embolization in 1476 Patients | 8.7 | 13 | Citations (PDF) |
| 19 | Percutaneous Endoscopy and Image-guided Retrieval of Dropped Gallstones – A Case Series | 0.9 | 6 | Citations (PDF) |
| 20 | Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study | 0.6 | 3 | Citations (PDF) |
| 21 | Interventional radiology and the liver vasculature: A personal perspective | 1.3 | 0 | Citations (PDF) |
| 22 | Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study | 3.4 | 6 | Citations (PDF) |
| 23 | Utility of pre-procedural [99mTc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based Segmentation | 5.5 | 1 | Citations (PDF) |
| 24 | Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma | 8.7 | 16 | Citations (PDF) |
| 25 | Percutaneous Cystic Duct Interventions and Drain Internalization for Calculous Cholecystitis in Patients Ineligible for Surgery | 1.1 | 12 | Citations (PDF) |
| 26 | Yttrium-90 Radiation Segmentectomy in Oligometastatic Secondary Hepatic Malignancies | 1.1 | 16 | Citations (PDF) |
| 27 | Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma | 1.1 | 40 | Citations (PDF) |
| 28 | Portal Vein Recanalization–Transjugular Intrahepatic Portosystemic Shunt (PVR-TIPS) Facilitates Liver Transplantation in Cirrhotic Patients with Occlusive Portal Vein Thrombosis | 1.0 | 17 | Citations (PDF) |
| 29 | Chemical Shift MRI Monitoring of Chemoembolization Delivery for Hepatocellular Carcinoma: Multicenter Feasibility of Initial Clinical Translation | 3.5 | 0 | Citations (PDF) |
| 30 | Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma | 5.5 | 4 | Citations (PDF) |
| 31 | North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension | 6.0 | 213 | Citations (PDF) |
| 32 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update | 4.2 | 3,884 | Citations (PDF) |
| 33 | TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC | 1.7 | 53 | Citations (PDF) |
| 34 | Preoperative portal vein recanalization–transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation | 4.5 | 25 | Citations (PDF) |
| 35 | A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study | 5.5 | 86 | Citations (PDF) |
| 36 | Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group | 0.3 | 19 | Citations (PDF) |
| 37 | Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database | 5.1 | 1 | Citations (PDF) |
| 38 | Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure | 2.5 | 21 | Citations (PDF) |
| 39 | Primary retrograde urinary drainage using image and endoscopy guidance via urostomies | 1.4 | 1 | Citations (PDF) |
| 40 | Abstract No. 84 Impact of portal hypertension on outcomes of splenic arterial aneurysm embolization: a multi-institutional analysis | 1.1 | 0 | Citations (PDF) |
| 41 | Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort | 1.7 | 28 | Citations (PDF) |
| 42 | Interventional treatment of hepatocellular carcinoma | 4.2 | 27 | Citations (PDF) |
| 43 | Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines | 2.4 | 11 | Citations (PDF) |
| 44 | The 2022 Society of Interventional Radiology Annual Meeting Dotter Lecture: Mentorship | 1.1 | 1 | Citations (PDF) |
| 45 | An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma | 3.4 | 12 | Citations (PDF) |
| 46 | Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group | 5.5 | 99 | Citations (PDF) |
| 47 | What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association | 4.5 | 37 | Citations (PDF) |
| 48 | Hepatocellular carcinoma | 62.1 | 2,147 | Citations (PDF) |
| 49 | How Endoscopic Guidance Augments Nonvascular Image-guided Interventions | 3.6 | 8 | Citations (PDF) |
| 50 | Controversies in Prostate Artery Embolization: Future Best Practice | 1.0 | 5 | Citations (PDF) |
| 51 | Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐Year Experience in 207‐Patient Cohort | 10.1 | 93 | Citations (PDF) |
| 52 | Management of Symptomatic Portal Cavernoma Cholangiopathy With Transplenic Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt | 10.1 | 13 | Citations (PDF) |
| 53 | Access Site for Visceral Arterial Interventions: Counterpoint—Transfemoral Remains the Way to Go | 4.1 | 1 | Citations (PDF) |
| 54 | Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model | 1.1 | 4 | Citations (PDF) |
| 55 | Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation | 1.1 | 9 | Citations (PDF) |
| 56 | Does significantly elevated lung shunt fraction (LSF >20%) promote extrahepatic progression in patients with hepatocellular carcinoma treated with radioembolization? | 1.1 | 1 | Citations (PDF) |
| 57 | Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis | 1.7 | 41 | Citations (PDF) |
| 58 | ACR–ABS–ACNM–ASTRO–SIR–SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies | 1.1 | 9 | Citations (PDF) |
| 59 | Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial | 2.6 | 55 | Citations (PDF) |
| 60 | Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study | 10.1 | 487 | Citations (PDF) |
| 61 | TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard‐of‐Care Therapy | 10.1 | 64 | Citations (PDF) |
| 62 | Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation | 1.1 | 18 | Citations (PDF) |
| 63 | Role of Interventional Radiology in the Management of Acute Cholangitis | 1.0 | 7 | Citations (PDF) |
| 64 | Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma | 1.7 | 24 | Citations (PDF) |
| 65 | Reassessment of the lung dose limits for radioembolization | 1.1 | 21 | Citations (PDF) |
| 66 | Future Directions of Percutaneous Biliary Interventions | 1.0 | 6 | Citations (PDF) |
| 67 | Contemporary Review of Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia | 0.3 | 1 | Citations (PDF) |
| 68 | Image-guided Interventions with Endoscopic Guidance | 0.3 | 1 | Citations (PDF) |
| 69 | 934P The TARGET study: A global investigation of advanced dosimetry for transarterial radioembolization of hepatocellular carcinoma with yttrium-90 glass microspheres | 9.9 | 1 | Citations (PDF) |
| 70 | Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative | 8.7 | 162 | Citations (PDF) |
| 71 | Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review | 3.6 | 77 | Citations (PDF) |
| 72 | Post-embolization outcomes of splenic artery pseudoaneurysms: A single-center experience | 1.3 | 14 | Citations (PDF) |
| 73 | International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres | 5.5 | 222 | Citations (PDF) |
| 74 | Extrahepatic Applications of Yttrium-90 Radioembolization | 1.0 | 5 | Citations (PDF) |
| 75 | Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach | 1.0 | 4 | Citations (PDF) |
| 76 | Trans-cervical thoracic duct embolization for post-surgical left Chylothorax in a patient with multifocal lymphatic malformations | 1.2 | 1 | Citations (PDF) |
| 77 | Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes | 1.0 | 16 | Citations (PDF) |
| 78 | Development of Research Agenda in Prostate Artery Embolization: Summary of Society of Interventional Radiology Consensus Panel | 1.1 | 2 | Citations (PDF) |
| 79 | Percutaneous Access of the Modified Hutson Loop for Retrograde Cholangiography, Endoscopy, and Biliary Interventions | 1.1 | 16 | Citations (PDF) |
| 80 | The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors | 0.9 | 171 | Citations (PDF) |
| 81 | Abstract No. 716 Long-term outcomes of Yttrium-90 radioembolization for hepatocellular carcinoma due to underlying non-alcoholic steatohepatitis | 1.1 | 0 | Citations (PDF) |
| 82 | Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma | 0.3 | 4 | Citations (PDF) |
| 83 | Excimer Laser Sheath–Assisted Retrieval of “Closed‐Cell” Design Inferior Vena Cava Filters | 4.0 | 6 | Citations (PDF) |
| 84 | Yttrium-90 Portal Vein Radioembolization in Sprague–Dawley Rats: Dose-Dependent Imaging and Pathological Changes in Normal Liver | 1.7 | 2 | Citations (PDF) |
| 85 | Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process | 3.8 | 2 | Citations (PDF) |
| 86 | Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model | 1.7 | 6 | Citations (PDF) |
| 87 | Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective | 22.8 | 37 | Citations (PDF) |
| 88 | Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation | 4.2 | 55 | Citations (PDF) |
| 89 | 4:03 PM Abstract No. 29 Streamlining Y90 in early stage hepatocellular carcinoma by eliminating the lung shunt study: analysis of a 403-patient cohort | 1.1 | 0 | Citations (PDF) |
| 90 | Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study | 1.1 | 11 | Citations (PDF) |
| 91 | Adverse Events Related to Partial Splenic Embolization for the Treatment of Hypersplenism: A Systematic Review | 1.1 | 38 | Citations (PDF) |
| 92 | Yttrium-90 Radioembolization and Tumor Hypoxia: Gas-challenge BOLD Imaging in the VX2 Rabbit Model of Hepatocellular Carcinoma | 2.7 | 9 | Citations (PDF) |
| 93 | Systematic Review and Meta-analysis Comparing Prostatic Artery Embolization to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia | 1.7 | 64 | Citations (PDF) |
| 94 | Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants | 5.5 | 146 | Citations (PDF) |
| 95 | Contemporary Systematic Review of Health-Related Quality of Life Outcomes in Locoregional Therapies for Hepatocellular Carcinoma | 1.1 | 21 | Citations (PDF) |
| 96 | Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma | 3.8 | 141 | Citations (PDF) |
| 97 | Single-session inferior vena cava filter removal, recanalization, and endovenous reconstruction for chronic iliocaval thrombosis | 1.7 | 20 | Citations (PDF) |
| 98 | Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization | 3.8 | 58 | Citations (PDF) |
| 99 | 03:54 PM Abstract No. 331 Radioembolization for hepatocellular carcinoma patients within Milan criteria: bridging and beyond | 1.1 | 1 | Citations (PDF) |
| 100 | Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma | 1.1 | 16 | Citations (PDF) |
| 101 | Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation | 1.7 | 7 | Citations (PDF) |
| 102 | Percutaneous management of malignant biliary disease | 1.5 | 22 | Citations (PDF) |
| 103 | Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Société Française de Radiologie, and the British Society of Interventional Radiology | 1.1 | 115 | Citations (PDF) |
| 104 | Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma | 4.9 | 39 | Citations (PDF) |
| 105 | Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis | 4.2 | 111 | Citations (PDF) |
| 106 | Cost-Effectiveness of a Guided Peripherally Inserted Central Catheter Placement System: A Single-Center Cohort Study | 1.1 | 22 | Citations (PDF) |
| 107 | Is hepatectomy safe following Yttrium-90 therapy? A multi-institutional international experience | 0.3 | 15 | Citations (PDF) |
| 108 | Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort | 5.5 | 17 | Citations (PDF) |
| 109 | Endovascular Management of Acquired Hepatic Arterial–Portal Venous Malformations | 1.7 | 3 | Citations (PDF) |
| 110 | Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin | 1.7 | 33 | Citations (PDF) |
| 111 | Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma | 8.7 | 243 | Citations (PDF) |
| 112 | MRI‐guided interventional natural killer cell delivery for liver tumor treatment | 2.6 | 29 | Citations (PDF) |
| 113 | Perceptions of Quality in Interventional Oncology | 1.1 | 1 | Citations (PDF) |
| 114 | Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study | 1.1 | 20 | Citations (PDF) |
| 115 | Development of National Research and Clinical Agendas for Patient-Reported Outcomes in IR: Proceedings from a Multidisciplinary Consensus Panel | 1.1 | 16 | Citations (PDF) |
| 116 | 90Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort | 5.1 | 78 | Citations (PDF) |
| 117 | 18F-FDG PET Biomarkers Help Detect Early Metabolic Response to Irreversible Electroporation and Predict Therapeutic Outcomes in a Rat Liver Tumor Model | 8.7 | 9 | Citations (PDF) |
| 118 | Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience | 10.1 | 219 | Citations (PDF) |
| 119 | Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma | 16.8 | 123 | Citations (PDF) |
| 120 | Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses | 10.1 | 45 | Citations (PDF) |
| 121 | Radioembolization in Advanced Hepatocellular Carcinoma | 16.9 | 9 | Citations (PDF) |
| 122 | Abstract No. 548 A score based on routine laboratory values as a prognosticator of survival in hepatocellular carcinoma | 1.1 | 0 | Citations (PDF) |
| 123 | Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma | 1.1 | 93 | Citations (PDF) |
| 124 | Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma | 2.7 | 4 | Citations (PDF) |
| 125 | Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma | 1.7 | 25 | Citations (PDF) |
| 126 | Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study | 1.4 | 47 | Citations (PDF) |
| 127 | 4:20 PM Abstract No. 432 Prospective single-center investigational device exemption study of prostate artery embolization for lower urinary tract symptoms | 1.1 | 1 | Citations (PDF) |
| 128 | MR imaging findings of the prostate gland following prostate artery embolization: results from a prospective phase 2 study | 1.7 | 17 | Citations (PDF) |
| 129 | Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals | 4.2 | 153 | Citations (PDF) |
| 130 | Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review | 1.7 | 51 | Citations (PDF) |
| 131 | JOURNAL CLUB: Four-Dimensional Flow MRI–Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism | 4.1 | 19 | Citations (PDF) |
| 132 | Defining Prolonged Dwell Time: When Are Advanced Inferior Vena Cava Filter Retrieval Techniques Necessary? | 4.8 | 46 | Citations (PDF) |
| 133 | Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization | 2.8 | 47 | Citations (PDF) |
| 134 | The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors | 0.9 | 303 | Citations (PDF) |
| 135 | Bimetal nano-radiosensitizers for 90Y radioembolization | 1.1 | 1 | Citations (PDF) |
| 136 | Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma | 1.7 | 14 | Citations (PDF) |
| 137 | Analysis of the RENAL and mRENAL Scores and the Relative Importance of Their Components in the Prediction of Complications and Local Progression after Percutaneous Renal Cryoablation | 1.1 | 35 | Citations (PDF) |
| 138 | Response by Desai et al to Letter Regarding Article, “Defining Prolonged Dwell Time: When Are Advanced Inferior Vena Cava Filter Retrieval Techniques Necessary? An Analysis in 762 Procedures” | 4.8 | 6 | Citations (PDF) |
| 139 | Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort | 1.1 | 144 | Citations (PDF) |
| 140 | Reminiscing on Remnants: Imaging of Meckel Diverticulum and Its Complications in Adults | 4.1 | 32 | Citations (PDF) |
| 141 | Fluoroscopic Radiation Exposure in Chemoembolization and Radioembolization: Results from a Prospective Randomized Study | 1.1 | 4 | Citations (PDF) |
| 142 | Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures | 1.1 | 39 | Citations (PDF) |
| 143 | Interventional radiology in the management of the liver transplant patient | 2.5 | 21 | Citations (PDF) |
| 144 | Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection | 5.5 | 20 | Citations (PDF) |
| 145 | Progressive multifocal leukoencephalopathy in patients receiving rituximab and cyclophosphamide after haplo-identical T-cell replete transplantation and review of the literature | 1.7 | 1 | Citations (PDF) |
| 146 | Retrievable IVC Filters: Comprehensive Review of Device-related Complications and Advanced Retrieval Techniques | 3.6 | 71 | Citations (PDF) |
| 147 | Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver | 1.1 | 70 | Citations (PDF) |
| 148 | Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy | 1.1 | 144 | Citations (PDF) |
| 149 | Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions | 1.1 | 128 | Citations (PDF) |
| 150 | Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy | 6.0 | 39 | Citations (PDF) |
| 151 | Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases | 1.7 | 20 | Citations (PDF) |
| 152 | Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma | 1.7 | 26 | Citations (PDF) |
| 153 | Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience | 1.7 | 14 | Citations (PDF) |
| 154 | Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant | 2.3 | 4 | Citations (PDF) |
| 155 | Making the Case: Intra-arterial Therapy for Less Common Metastases | 1.0 | 14 | Citations (PDF) |
| 156 | New Developments in Interventional Oncology | 1.8 | 14 | Citations (PDF) |
| 157 | Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans‐splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization | 10.1 | 53 | Citations (PDF) |
| 158 | Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Technical Considerations | 1.1 | 111 | Citations (PDF) |
| 159 | Factors that complicate filter retrieval: Is there a dominant issue? | 1.1 | 0 | Citations (PDF) |
| 160 | Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival | 1.1 | 15 | Citations (PDF) |
| 161 | Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma | 3.3 | 150 | Citations (PDF) |
| 162 | Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial? | 3.9 | 20 | Citations (PDF) |
| 163 | A Dedicated Inferior Vena Cava Filter Service Line: How to Optimize Your Practice | 1.0 | 23 | Citations (PDF) |
| 164 | The Utility of Unilobar Technetium-99m Macroaggregated Albumin to Predict Pulmonary Toxicity In Bilobar Hepatocellular Carcinoma prior to Yttrium-90 Radioembolization | 1.1 | 9 | Citations (PDF) |
| 165 | Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis | 3.6 | 13 | Citations (PDF) |
| 166 | Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib | 1.1 | 26 | Citations (PDF) |
| 167 | Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review | 4.1 | 39 | Citations (PDF) |
| 168 | Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma | 0.9 | 642 | Citations (PDF) |
| 169 | The Role of Four-Dimensional Flow MR Imaging in the Diagnosis and Treatment of a Splenic Arteriovenous Fistula | 1.1 | 1 | Citations (PDF) |
| 170 | Same-day 90Y radioembolization: implementing a new treatment paradigm | 5.5 | 60 | Citations (PDF) |
| 171 | ■ ABSTRACT OF THE YEAR Independent analysis of albumin-bilirubin (ALBI) grade in a 765 patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma | 1.1 | 1 | Citations (PDF) |
| 172 | Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma | 1.1 | 70 | Citations (PDF) |
| 173 | Assessment of non‐surgical versus surgical therapy for localized hepatocellular carcinoma | 1.5 | 18 | Citations (PDF) |
| 174 | 90Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes | 1.5 | 108 | Citations (PDF) |
| 175 | Percutaneous Cryoablation for the Treatment of Primary and Metastatic Lung Tumors: Identification of Risk Factors for Recurrence and Major Complications | 1.1 | 57 | Citations (PDF) |
| 176 | 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study | 5.1 | 88 | Citations (PDF) |
| 177 | Yttrium-90 Radioembolization for Hepatocellular Carcinoma | 4.9 | 18 | Citations (PDF) |
| 178 | Hepatic imaging following intra-arterial embolotherapy | 1.7 | 35 | Citations (PDF) |
| 179 | Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria | 1.1 | 111 | Citations (PDF) |
| 180 | Threshold for Enhancement in Treated Hepatocellular Carcinoma on MDCT: Effect on Necrosis Quantification | 4.1 | 8 | Citations (PDF) |
| 181 | Types of Research Bias Encountered in IR | 1.1 | 6 | Citations (PDF) |
| 182 | Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival | 1.7 | 97 | Citations (PDF) |
| 183 | Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference | 0.3 | 172 | Citations (PDF) |
| 184 | Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma | 10.1 | 62 | Citations (PDF) |
| 185 | Pretransplant Portal Vein Recanalization—Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis | 2.1 | 148 | Citations (PDF) |
| 186 | Transarterial approaches to primary and secondary hepatic malignancies | 70.7 | 51 | Citations (PDF) |
| 187 | Portal Vein Recanalization–Transjugular Intrahepatic Portosystemic Shunt Using the Transsplenic Approach to Achieve Transplant Candidacy in Patients with Chronic Portal Vein Thrombosis | 1.1 | 109 | Citations (PDF) |
| 188 | A Comparison of Retrievability: Celect versus Option Filter | 1.1 | 21 | Citations (PDF) |
| 189 | Prostatic Arterial Embolization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia | 8.7 | 24 | Citations (PDF) |
| 190 | Locoregional Therapy of Hepatocellular Carcinoma | 3.5 | 30 | Citations (PDF) |
| 191 | Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance | 1.3 | 3 | Citations (PDF) |
| 192 | Effect of TIPS placement on portal and splanchnic arterial blood flow in 4-dimensional flow MRI | 3.6 | 45 | Citations (PDF) |
| 193 | Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization | 5.1 | 25 | Citations (PDF) |
| 194 | Retrieval of Inferior Vena Cava Filters With Prolonged Dwell Time | 10.6 | 38 | Citations (PDF) |
| 195 | Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction? | 5.5 | 14 | Citations (PDF) |
| 196 | Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion | 1.7 | 247 | Citations (PDF) |
| 197 | Side Effects of Yttrium-90 Radioembolization | 2.6 | 165 | Citations (PDF) |
| 198 | Transarterial Chemoembolization and Radioembolization | 3.1 | 90 | Citations (PDF) |
| 199 | Perfusion Reduction at Transcatheter Intraarterial Perfusion MR Imaging: A Promising Intraprocedural Biomarker to Predict Transplant-Free Survival during Chemoembolization of Hepatocellular Carcinoma | 8.7 | 19 | Citations (PDF) |
| 200 | Unresectable Solitary Hepatocellular Carcinoma Not Amenable to Radiofrequency Ablation: Multicenter Radiology-Pathology Correlation and Survival of Radiation Segmentectomy | 10.1 | 298 | Citations (PDF) |
| 201 | Seven-Tesla Magnetic Resonance Imaging Accurately Quantifies Intratumoral Uptake of Therapeutic Nanoparticles in the McA Rat Model of Hepatocellular Carcinoma | 6.8 | 5 | Citations (PDF) |
| 202 | Hepatic yttrium-90 radioembolization for metastatic melanoma | 1.5 | 24 | Citations (PDF) |
| 203 | Ethanol Embolotherapy of Vascular Malformations: Clinical Outcomes at a Single Center | 1.1 | 56 | Citations (PDF) |
| 204 | Tumor Growth Kinetics Versus RECIST to Assess Response to Locoregional Therapy in Breast Cancer Liver Metastases | 2.7 | 13 | Citations (PDF) |
| 205 | Prospective randomized pilot study of Y90 +/− sorafenib as bridge to transplantation in hepatocellular carcinoma | 4.2 | 90 | Citations (PDF) |
| 206 | Localized Hyperthermia with Iron Oxide–Doped Yttrium Microparticles: Steps toward Image-Guided Thermoradiotherapy in Liver Cancer | 1.1 | 18 | Citations (PDF) |
| 207 | Outpatient Single-Session Yttrium-90 Glass Microsphere Radioembolization | 1.1 | 63 | Citations (PDF) |
| 208 | Recommendations for management of patients with neuroendocrine liver metastases | 27.4 | 485 | Citations (PDF) |
| 209 | Image-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update | 1.1 | 433 | Citations (PDF) |
| 210 | Transarterial Chemoembolization and Yittrium-90 for Liver Cancer and Other Lesions | 3.5 | 13 | Citations (PDF) |
| 211 | Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy | 1.1 | 67 | Citations (PDF) |
| 212 | Reply to "Hepatic Radioembolization as a True Single-Session Treatment" | 1.1 | 5 | Citations (PDF) |
| 213 | Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy | 5.5 | 89 | Citations (PDF) |
| 214 | Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization | 1.5 | 52 | Citations (PDF) |
| 215 | MR Imaging Enables Measurement of Therapeutic Nanoparticle Uptake in Rat N1-S1 Liver Tumors after Nanoablation | 1.1 | 3 | Citations (PDF) |
| 216 | Comparative Study of Staging Systems for Hepatocellular Carcinoma in 428 Patients Treated with Radioembolization | 1.1 | 21 | Citations (PDF) |
| 217 | Rationale of transcatheter intra-arterial therapies of hepatic cancers | 1.0 | 2 | Citations (PDF) |
| 218 | Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC? | 1.9 | 25 | Citations (PDF) |
| 219 | Imaging tumor response following liver-directed intra-arterial therapy | 1.9 | 29 | Citations (PDF) |
| 220 | Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression | 4.2 | 116 | Citations (PDF) |
| 221 | Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science | 1.1 | 36 | Citations (PDF) |
| 222 | Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis | 2.3 | 154 | Citations (PDF) |
| 223 | Image-Guided Local Delivery Strategies Enhance Therapeutic Nanoparticle Uptake in Solid Tumors | 15.3 | 53 | Citations (PDF) |
| 224 | Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part I | 1.1 | 30 | Citations (PDF) |
| 225 | Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma | 4.0 | 42 | Citations (PDF) |
| 226 | A prospective comparison of retrievability: celect versus option filter | 1.1 | 0 | Citations (PDF) |
| 227 | The role of potentially retrievable inferior vena cava filters in oncology patients: a comprehensive single center experience | 1.1 | 0 | Citations (PDF) |
| 228 | Embolization of the gastroduodenal and right gastric arteries prior to radioembolization with glass microspheres: is it always necessary? | 1.1 | 0 | Citations (PDF) |
| 229 | Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study | 4.9 | 89 | Citations (PDF) |
| 230 | Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection | 4.2 | 256 | Citations (PDF) |
| 231 | Chemoembolization and Radioembolization for Hepatocellular Carcinoma | 6.0 | 96 | Citations (PDF) |
| 232 | Radioembolization of Renal Cell Carcinoma Using Yttrium-90 Microspheres | 1.1 | 18 | Citations (PDF) |
| 233 | Portal vein thromboembolectomy/TIPS: a novel preliver transplant interventional approach to rendering the untransplantable patient transplant-ready | 1.1 | 3 | Citations (PDF) |
| 234 | Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization | 6.0 | 242 | Citations (PDF) |
| 235 | Yttrium-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts | 1.1 | 24 | Citations (PDF) |
| 236 | Comparison of image-guided intratumoral versus intravenous delivery of therapeutic nanoparticles for the treatment of hepatocellular carcinoma | 1.1 | 2 | Citations (PDF) |
| 237 | Response assessment methodologies in hepatocellular carcinoma: Complexities in the era of local and systemic treatments | 4.2 | 17 | Citations (PDF) |
| 238 | The role of potentially retrievable inferior vena cava filters in high-risk patients undergoing joint arthroplasty | 1.1 | 0 | Citations (PDF) |
| 239 | ■ Dr. Constantin Cope Medical Student Research Award High-field MRI accurately quantifies tumor uptake of therapeutic iron-oxide nanoparticles in the McA-RH7777 rat model of liver cancer | 1.1 | 0 | Citations (PDF) |
| 240 | Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part II | 1.1 | 30 | Citations (PDF) |
| 241 | Optional or Permanent: Clinical Factors that Optimize Inferior Vena Cava Filter Utilization | 1.1 | 37 | Citations (PDF) |
| 242 | Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials | 1.1 | 18 | Citations (PDF) |
| 243 | Yttrium-90 Radioembolization for Intrahepatic Cholangiocarcinoma: Safety, Response, and Survival Analysis | 1.1 | 212 | Citations (PDF) |
| 244 | Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement | 0.3 | 4 | Citations (PDF) |
| 245 | Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives | 10.1 | 174 | Citations (PDF) |
| 246 | Minimally Invasive Therapies for Hepatic Malignancy | 1.2 | 8 | Citations (PDF) |
| 247 | Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging | 3.6 | 92 | Citations (PDF) |
| 248 | Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib | 10.1 | 72 | Citations (PDF) |
| 249 | Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort | 5.5 | 26 | Citations (PDF) |
| 250 | Radioembolization for the Treatment of Liver Tumors | 1.3 | 128 | Citations (PDF) |
| 251 | Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases | 1.3 | 22 | Citations (PDF) |
| 252 | Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors | 1.3 | 24 | Citations (PDF) |
| 253 | Radioembolization in the Treatment of Unresectable Liver Tumors | 1.3 | 41 | Citations (PDF) |
| 254 | Locoregional Chemoembolic Delivery: Prediction With Transcatheter Intraarterial Perfusion MRI | 4.1 | 7 | Citations (PDF) |
| 255 | Integrating Radioembolization into the Treatment Paradigm for Metastatic Neuroendocrine Tumors in the Liver | 1.3 | 32 | Citations (PDF) |
| 256 | Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies | 3.9 | 41 | Citations (PDF) |
| 257 | Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes | 1.5 | 149 | Citations (PDF) |
| 258 | Optimizing IVC Filter Utilization: A Prospective Study of the Impact of Interventional Radiologist Consultation | 2.3 | 13 | Citations (PDF) |
| 259 | Abstract No LB10: Chemoradiation for hepatic malignancies: dose-escalating study of Y90 with capecitabine for metastatic disease to the liver | 1.1 | 0 | Citations (PDF) |
| 260 | Abstract No. 294: Optimizing IVC filter utilization: a prospective study of the impact of IR consultation | 1.1 | 0 | Citations (PDF) |
| 261 | MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy | 2.7 | 30 | Citations (PDF) |
| 262 | Abstract No. 165: Survival in patients with hepatic colorectal metastases: 10 year experience in 180 patients treated with Yttrium-90 radioembolization | 1.1 | 0 | Citations (PDF) |
| 263 | Abstract No. 197: Yttrium-90 radioembolization for hepatic metastatic melanoma: a single center experience | 1.1 | 0 | Citations (PDF) |
| 264 | Quality Improvement Guidelines for Transhepatic Arterial Chemoembolization, Embolization, and Chemotherapeutic Infusion for Hepatic Malignancy | 1.1 | 167 | Citations (PDF) |
| 265 | Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis | 4.2 | 90 | Citations (PDF) |
| 266 | Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres | 1.5 | 203 | Citations (PDF) |
| 267 | Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients | 10.1 | 69 | Citations (PDF) |
| 268 | Research Reporting Standards for Radioembolization of Hepatic Malignancies | 1.1 | 198 | Citations (PDF) |
| 269 | Intraprocedural Transcatheter Intra-arterial Perfusion MRI as a Predictor of Tumor Response to Chemoembolization for Hepatocellular Carcinoma | 2.7 | 17 | Citations (PDF) |
| 270 | Invited Commentary | 1.1 | 1 | Citations (PDF) |
| 271 | Abstract No. 234: Segmentation and automated measurements of hepatocellular carcinomas in liver CT scans: Comparison to pathology | 1.1 | 0 | Citations (PDF) |
| 272 | Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma | 0.9 | 619 | Citations (PDF) |
| 273 | Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times | 0.9 | 153 | Citations (PDF) |
| 274 | Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic–pathologic correlation | 4.2 | 145 | Citations (PDF) |
| 275 | Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer | 1.1 | 41 | Citations (PDF) |
| 276 | Radioembolization for Hepatocellular Carcinoma | 1.3 | 95 | Citations (PDF) |
| 277 | General Selection Criteria of Patients for Radioembolization of Liver Tumors | 1.3 | 73 | Citations (PDF) |
| 278 | Radioembolization for Primary and Metastatic Liver Cancer | 2.7 | 86 | Citations (PDF) |
| 279 | Internal Pair Production of 90Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept | 5.1 | 120 | Citations (PDF) |
| 280 | Radiologic Assessment of Response to Therapy: Comparison of RECIST Versions 1.1 and 1.0 | 3.6 | 84 | Citations (PDF) |
| 281 | Four‐dimensional transcatheter intraarterial perfusion MRI monitoring of radiofrequency ablation of rabbit VX2 liver tumors | 3.4 | 8 | Citations (PDF) |
| 282 | Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization | 1.5 | 250 | Citations (PDF) |
| 283 | In Reply to Dr. Kao et al. | 1.5 | 1 | Citations (PDF) |
| 284 | Response to Treatment Series: Part 2, Tumor Response Assessment—Using New and Conventional Criteria | 4.1 | 70 | Citations (PDF) |
| 285 | Quantitative 4D Transcatheter Intraarterial Perfusion MRI for Standardizing Angiographic Chemoembolization Endpoints | 4.1 | 15 | Citations (PDF) |
| 286 | Hepatic Radioembolization Complicated by Gastrointestinal Ulceration | 1.0 | 28 | Citations (PDF) |
| 287 | Chemoembolization Endpoints: Effect on Survival Among Patients With Hepatocellular Carcinoma | 4.1 | 72 | Citations (PDF) |
| 288 | Hepatic Radioembolization Complicated by Abscess | 1.0 | 15 | Citations (PDF) |
| 289 | Transcatheter Intraarterial Therapies: Rationale and Overview | 8.7 | 232 | Citations (PDF) |
| 290 | Treating and Downstaging Hepatocellular Carcinoma in the Caudate Lobe with Yttrium-90 Radioembolization | 1.7 | 33 | Citations (PDF) |
| 291 | Radioembolization (Yttrium-90 Microspheres) for Primary and Metastatic Hepatic Malignancies | 1.8 | 81 | Citations (PDF) |
| 292 | Yttrium-90 Radioembolization in the Management of Liver Malignancies | 1.9 | 20 | Citations (PDF) |
| 293 | Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma | 3.4 | 22 | Citations (PDF) |
| 294 | Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement | 0.3 | 72 | Citations (PDF) |
| 295 | Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort | 8.7 | 148 | Citations (PDF) |
| 296 | Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma | 16.5 | 178 | Citations (PDF) |
| 297 | Fluoro-2-Deoxy-
d
-Glucose Positron Emission Tomography/Computed Tomography Predicts Extrahepatic Metastatic Potential of Colorectal Metastasis: A Practical Guide for Yttrium-90 Microsphere Liver-Directed Therapy | 1.2 | 5 | Citations (PDF) |
| 298 | Does Multidetector CT Attenuation Change in Colon Cancer Liver Metastases Treated with90Y Help Predict Metabolic Activity at FDG PET? | 8.7 | 32 | Citations (PDF) |
| 299 | Abstract No. 7: Placement and retrieval of optional inferior vena cava (IVC) filters: The impact of a dedicated IVC filter clinic | 1.1 | 0 | Citations (PDF) |
| 300 | Yttrium-90 Radioembolization for Liver Malignancies: Prognostic Factors Associated with Survival | 1.1 | 44 | Citations (PDF) |
| 301 | Abstract No. 33: Radiation segmentectomy: A novel approach to increase safety and efficacy of radioembolization | 1.1 | 0 | Citations (PDF) |
| 302 | Safety of Yttrium-90 Microsphere Radioembolization in Patients with Biliary Obstruction | 1.1 | 16 | Citations (PDF) |
| 303 | Agreement between Competing Imaging Measures of Response of Hepatocellular Carcinoma to Yttrium-90 Radioembolization | 1.1 | 38 | Citations (PDF) |
| 304 | Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes | 0.9 | 1,023 | Citations (PDF) |
| 305 | Improving Inferior Vena Cava Filter Retrieval Rates: Impact of a Dedicated Inferior Vena Cava Filter Clinic | 1.1 | 194 | Citations (PDF) |
| 306 | A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization | 4.5 | 584 | Citations (PDF) |
| 307 | Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres # | 10.1 | 251 | Citations (PDF) |
| 308 | Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres | 4.0 | 169 | Citations (PDF) |
| 309 | Internal radioembolization for colorectal carcinoma liver metastases | 0.1 | 0 | Citations (PDF) |
| 310 | Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors | 1.5 | 246 | Citations (PDF) |
| 311 | Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization | 2.3 | 231 | Citations (PDF) |
| 312 | Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study | 1.1 | 33 | Citations (PDF) |
| 313 | Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review | 1.1 | 336 | Citations (PDF) |
| 314 | Development of a VX2 Pancreatic Cancer Model in Rabbits: A Pilot Study | 1.1 | 16 | Citations (PDF) |
| 315 | The Role of Tumor Vascularity in Predicting Survival after Yttrium-90 Radioembolization for Liver Metastases | 1.1 | 58 | Citations (PDF) |
| 316 | Neuroendocrine Tumors | 12.6 | 191 | Citations (PDF) |
| 317 | Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease | 1.3 | 27 | Citations (PDF) |
| 318 | Hepatic Abscess After Yttrium-90 Radioembolization for Islet-Cell Tumor Hepatic Metastasis | 1.7 | 16 | Citations (PDF) |
| 319 | Radiologic–Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization | 1.7 | 89 | Citations (PDF) |
| 320 | A Simple Fluoroscopic Approach to Percutaneous Transgastric Cystgastrostomy with Internalized Drainage Catheter for Treatment of Pancreatic Pseudocysts: Report of Two Cases | 2.1 | 3 | Citations (PDF) |
| 321 | Transjugular Intrahepatic Portosystemic Shunt with Thrombectomy for the Treatment of Portal Vein Thrombosis After Liver Transplantation | 2.1 | 19 | Citations (PDF) |
| 322 | Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | 10.1 | 576 | Citations (PDF) |
| 323 | Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres | 2.1 | 141 | Citations (PDF) |
| 324 | Radiographic Response to Yttrium-90 Radioembolization in Anterior Versus Posterior Liver Segments | 1.7 | 15 | Citations (PDF) |
| 325 | Treatment of unresectable cholangiocarcinoma using yttrium‐90 microspheres | 4.0 | 192 | Citations (PDF) |
| 326 | Thoracic Duct Embolization: A New Treatment for Massive Leak After Neck Dissection | 1.4 | 43 | Citations (PDF) |
| 327 | Tumor Response after Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Comparison of Diffusion-weighted Functional MR Imaging with Anatomic MR Imaging | 1.1 | 120 | Citations (PDF) |
| 328 | MR Imaging Perfusion Mismatch: A Technique to Verify Successful Targeting of Liver Tumors during Transcatheter Arterial Chemoembolization | 1.1 | 10 | Citations (PDF) |
| 329 | Biliary Sequelae following Radioembolization with Yttrium-90 Microspheres | 1.1 | 158 | Citations (PDF) |
| 330 | Comparison of Two Different Methods for Inoculating VX2 Tumors in Rabbit Livers and Hind Limbs | 1.1 | 60 | Citations (PDF) |
| 331 | Four-dimensional Transcatheter Intraarterial Perfusion MR Imaging for Monitoring Chemoembolization of Hepatocellular Carcinoma: Preliminary Results | 1.1 | 25 | Citations (PDF) |
| 332 | Comparison of Hypoxia-inducible Factor-1α Expression before and after Transcatheter Arterial Embolization in Rabbit VX2 Liver Tumors | 1.1 | 92 | Citations (PDF) |
| 333 | Radioembolization of Yttrium-90 Microspheres for Hepatic Malignancy | 1.0 | 54 | Citations (PDF) |
| 334 | Multimodality Imaging Following90Y Radioembolization: A Comprehensive Review and Pictorial Essay | 3.6 | 133 | Citations (PDF) |
| 335 | Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients | 1.3 | 422 | Citations (PDF) |
| 336 | Incidence of Radiation Pneumonitis After Hepatic Intra-Arterial Radiotherapy With Yttrium-90 Microspheres Assuming Uniform Lung Distribution | 1.3 | 168 | Citations (PDF) |
| 337 | 90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors | 4.6 | 226 | Citations (PDF) |
| 338 | Radiologic findings following Y90 radioembolization for primary liver malignancies | 1.9 | 98 | Citations (PDF) |
| 339 | Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review | 0.0 | 98 | Citations (PDF) |
| 340 | Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors | 2.3 | 32 | Citations (PDF) |
| 341 | Imaging of Hepatocellular Carcinoma After Treatment with Yttrium-90 Microspheres | 4.1 | 119 | Citations (PDF) |
| 342 | Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET | 4.1 | 122 | Citations (PDF) |
| 343 | Emerging Approaches in Hepatocellular Carcinoma | 2.3 | 16 | Citations (PDF) |
| 344 | Technical Aspects of Radioembolization with 90Y Microspheres | 1.1 | 131 | Citations (PDF) |
| 345 | Radiation Dose Limits and Liver Toxicities Resulting from Multiple Yttrium-90 Radioembolization Treatments for Hepatocellular Carcinoma | 1.1 | 110 | Citations (PDF) |
| 346 | A Comparison of Chemoembolization Endpoints Using Angiographic versus Transcatheter Intraarterial Perfusion/MR Imaging Monitoring | 1.1 | 71 | Citations (PDF) |
| 347 | Comparison of Transcatheter Intraarterial Perfusion MR Imaging and Fluorescent Microsphere Perfusion Measurements during Transcatheter Arterial Embolization of Rabbit Liver Tumors | 1.1 | 17 | Citations (PDF) |
| 348 | Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria | 1.1 | 62 | Citations (PDF) |
| 349 | Effect of Transcatheter Arterial Embolization on Levels of Hypoxia-inducible Factor-1α in Rabbit VX2 Liver Tumors | 1.1 | 65 | Citations (PDF) |
| 350 | Radioembolization with 90Y Microspheres: Technical Considerations | 1.1 | 13 | Citations (PDF) |
| 351 | 90Y Radioembolization of Metastatic Breast Cancer to the Liver: Toxicity, Imaging Response, Survival | 1.1 | 96 | Citations (PDF) |
| 352 | Radioembolization with 90Y Microspheres: Angiographic and Technical Considerations | 1.7 | 244 | Citations (PDF) |
| 353 | Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies | 1.1 | 669 | Citations (PDF) |
| 354 | Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies | 1.1 | 205 | Citations (PDF) |
| 355 | Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies | 1.1 | 193 | Citations (PDF) |
| 356 | Diffusion-weighted MR Imaging for Determination of Hepatocellular Carcinoma Response to Yttrium-90 Radioembolization | 1.1 | 117 | Citations (PDF) |
| 357 | Trans-arterial hepatic radioembolisation of yttrium-90 microspheres | 0.6 | 19 | Citations (PDF) |
| 358 | Successful Embolization of Hepatocelluar Carcinoma With Yttrium-90 Glass Microspheres Prior to Liver Transplantation | 1.7 | 28 | Citations (PDF) |
| 359 | Treatment of Unresectable Primary and Metastatic Liver Cancer with Yttrium-90 Microspheres (TheraSphere®): Assessment of Hepatic Arterial Embolization | 1.7 | 222 | Citations (PDF) |
| 360 | Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation | 1.5 | 319 | Citations (PDF) |
| 361 | Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver | 1.0 | 97 | Citations (PDF) |
| 362 | Regional Yttrium-90 Microsphere Treatment of Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma | 1.2 | 31 | Citations (PDF) |
| 363 | Use of yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report | 2.5 | 56 | Citations (PDF) |
| 364 | Complications of Renal Transplantation | 3.6 | 229 | Citations (PDF) |
| 365 | The Effect of Catheter-Directed CT Angiography on Yttrium-90 Radioembolization Treatment of Hepatocellular Carcinoma | 1.1 | 68 | Citations (PDF) |
| 366 | Assessment of the HCC Patient | 1.1 | 0 | Citations (PDF) |
| 367 | Primary Failure of Uterine Artery Embolization: Use of Magnetic Resonance Imaging to Select Patients for Repeated Embolization | 1.1 | 25 | Citations (PDF) |
| 368 | Determination of Optimal Gadolinium Concentration Using SSFP for Catheter-directed Contrast-enhanced Coronary MR Angiography1 | 2.7 | 5 | Citations (PDF) |
| 369 | 90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135–150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic Imaging | 1.1 | 168 | Citations (PDF) |
| 370 | Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival | 1.1 | 407 | Citations (PDF) |
| 371 | Real-time MRI Monitoring of Transcatheter Hepatic Artery Contrast Agent Delivery in Rabbits1 | 2.7 | 8 | Citations (PDF) |
| 372 | Reduction of Metastatic Load to Liver after Intraarterial Hepatic Yttrium-90 Radioembolization as Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomographic Imaging | 1.1 | 82 | Citations (PDF) |
| 373 | Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: Factors Associated with Liver Toxicities | 1.1 | 180 | Citations (PDF) |
| 374 | Feasibility of Blood Oxygenation Level–dependent MR Imaging to Monitor Hepatic Transcatheter Arterial Embolization in Rabbits | 1.1 | 30 | Citations (PDF) |
| 375 | Angiographic Considerations in Patients Undergoing Liver-directed Therapy | 1.1 | 243 | Citations (PDF) |
| 376 | Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: A Risk-Stratification Analysis | 1.1 | 115 | Citations (PDF) |
| 377 | Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis | 1.1 | 209 | Citations (PDF) |
| 378 | Treatment of unresectable hepatocellular carcinoma using intra-arterial yttrium-90 (TheraSphere): Report of a pilot trial | 0.9 | 0 | Citations (PDF) |
| 379 | Yttrium-90 Microspheres: Radiation Therapy for Unresectable Liver Cancer | 1.1 | 235 | Citations (PDF) |
| 380 | Radiologically guided percutaneous fine-needle aspiration biopsy of the liver: Retrospective study of 119 cases evaluating diagnostic effectiveness and clinical complications | 1.1 | 44 | Citations (PDF) |
| 381 | Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI | 5.5 | 154 | Citations (PDF) |
| 382 | Effect of MR Angiography on the Diagnosis and Treatment of Patients with Suspected Renovascular Disease | 1.1 | 4 | Citations (PDF) |
| 383 | 83 Long term local control and survival with preoperative cisplatin, continuous infusion 5-FU, and 45 Gy radiotherapy for esophageal cancer | 1.5 | 0 | Citations (PDF) |
| 384 | Management of Chylothorax by Percutaneous Catheterization and Embolization of the Thoracic Duct: Prospective Trial | 1.1 | 163 | Citations (PDF) |
| 385 | Digital Cameras: A Rapid and Inexpensive Means of Transferring Angiographic Images to Referring Clinicians | 1.1 | 1 | Citations (PDF) |
| 386 | The relationship between yttrium-90 glass microspheres specific activity, particle density and treatment outcomes in HCC and mCRC | 5.5 | 1 | Citations (PDF) |
| 387 | Successful Treatment of Portal Cavernoma Cholangiopathy With Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt (TIPS) | 0.6 | 0 | Citations (PDF) |
| 388 | Yttrium-90 Radioembolization for Androgen-Independent Prostate Cancer Metastasis to the Liver | 2.7 | 0 | Citations (PDF) |
| 389 | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma Definitive Therapy: Point—Simple, Reproducible, and Curative | 4.1 | 0 | Citations (PDF) |
| 390 | Survival and Surrogate Biomarkers in Interventional Oncology Trials: Pitfalls, Challenges, and Future Directions | 1.7 | 2 | Citations (PDF) |
| 391 | Safety and Feasibility of Yttrium-90 Radioembolization for Cirrhosis-Induced Splenomegaly and Thrombocytopenia: Results from an Investigational Device Exemption Study | 1.1 | 0 | Citations (PDF) |
| 392 | Radioembolization Practice in North America Versus Europe: Results from a Global Survey | 3.0 | 0 | Citations (PDF) |
| 393 | Assessing Quality-of-Life and Usability Associated With Percutaneous Drainage Catheters | 0.4 | 0 | Citations (PDF) |
| 394 | Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry | 5.5 | 0 | Citations (PDF) |
